Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2002

View Archived Issues

Euroscreen acquires license to hormone receptor technology

Orally active VEGFR tyrosine kinase inhibitor RWJ-417975 exerts antitumor activity in mouse models

Improved HIV protease inhibitors discovered at Merck & Co.

Histamine H3 receptor agonist discovered by European team

Clinical trials of drugs in development for neurological disorders presented in Denver

New clinical trial results with mitoxantrone reported at this week's AAN meeting

Clinical trials with botulinum toxins reported at the AAN meeting

Prolifix identifies hydroxamate-based inhibitors of HDAC with antitumor activity

VEGFR tyrosine kinase inhibitor enters clinical testing based on preclinical results

Xcytrin to enter confirmatory phase III trial in lung cancer patients

Human Genome Sciences updates achievements in first quarter of 2002

Patient treatment begun in phase I/IIa trial of ZYC-300

Discovery Partners and Xenon Genetics collaborate on metabolic syndrome drug discovery

Consensus awarded SBIR grant for AIDS drug development

Trial initiated for Reolysin in prostate cancer

AGIX-4207 I.V. well tolerated and safe in phase I trial

Phase III trial of high-dose Betaferon/Betaseron planned

Biogen launches long-term study comparing Avonex and Rebif in MS

NDA submitted for Eligard 30 mg for advanced prostate cancer

New bicyclic alphavbeta3 and/or alphavbeta5 antagonists under study at Pharmacia

Agents for cardiovascular disorders developed at Sanofi-Synthelabo

Pola identifies compounds that reverse multidrug resistance in cancer and infections

Dual adenosine A1 and A2A receptor antagonists and their use described in recent patent

GSK presents new series of potent and selective COX-2 inhibitors

Recent patent describes synthesis, activity and use of polyamine AMPA receptor antagonists

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...